Discovering Potential in Non-Cancer Medications: A Promising Breakthrough for Multiple Myeloma Patients

Simple Summary Multiple myeloma (MM) is a type of cancer that affects the blood and bone marrow. Each individual diagnosed with MM will inevitably experience a relapse or develop resistance to the prescribed treatment. The development of new pharmaceuticals is an expensive and time-consuming process, which requires the investigation of more efficient approaches. This review article explores the potential of repurposing current drugs, originally designed for other conditions, for the treatment of MM. This approach is more efficient and economical in comparison to the process of developing new drugs from scratch. For instance, thalidomide, initially used for several medical ailments, has shown effectiveness in treating MM. This study emphasizes the potential of repurposing common drugs, such as aspirin and statins, for the treatment of MM. This approach not only speeds up the availability of new treatments but also offers hope for better outcomes for patients with MM. Future investigations will give priority to determining the most effective dosages and integrating these repurposed drugs with traditional therapy to improve their effectiveness. Abstract MM is a common type of cancer that unfortunately leads to a significant number of deaths each year. The majority of the reported MM cases are detected in the advanced stages, posing significant challenges for treatment. Additionally, all MM patients eventually develop resistance or experience relapse; therefore, advances in treatment are needed. However, developing new anti-cancer drugs, especially for MM, requires significant financial investment and a lengthy development process. The study of drug repurposing involves exploring the potential of existing drugs for new therapeutic uses. This can significantly reduce both time and costs, which are typically a major concern for MM patients. The utilization of pre-existing non-cancer drugs for various myeloma treatments presents a highly efficient and cost-effective strategy, considering their prior preclinical and clinical development. The drugs have shown promising potential in targeting key pathways associated with MM progression and resistance. Thalidomide exemplifies the success that can be achieved through this strategy. This review delves into the current trends, the challenges faced by conventional therapies for MM, and the importance of repurposing drugs for MM. This review highlights a noncomprehensive list of conventional therapies that have potentially significant anti-myeloma properties and anti-neoplastic effects. Additionally, we offer valuable insights into the resources that can help streamline and accelerate drug repurposing efforts in the field of MM.